Nxera Pharma Co., Ltd. (FRA:JSS)

Nxera Pharma Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	28,461	36,203	49,065	66,557	60,087	40,008
Cash & Short-Term Investments	28,461	36,203	49,065	66,557	60,087	40,008
Cash Growth	-41.76%	-26.21%	-26.28%	10.77%	50.19%	160.22%
Accounts Receivable	7,597	6,695	5,064	2,462	2,138	939
Other Receivables	2,230	4,643	6,823	140	103	732
Receivables	9,827	11,338	11,887	2,602	2,241	1,671
Inventory	9,632	8,838	2,903	-	-	-
Prepaid Expenses	-	1,259	790	638	388	322
Other Current Assets	3,407	217	467	145	92	17
Total Current Assets	51,327	57,855	65,112	69,942	62,808	42,018
Property, Plant & Equipment	6,595	7,468	7,900	3,791	3,817	3,824
Long-Term Investments	4,491	4,550	3,308	1,801	6,145	4,687
Goodwill	25,869	25,693	24,623	15,306	-	14,134
Other Intangible Assets	49,940	51,911	52,291	8,577	24,215	11,802
Long-Term Deferred Tax Assets	5,933	4,021	3,964	-	-	-
Other Long-Term Assets	23	-	-	-	-	-
Total Assets	144,178	151,498	157,198	99,417	96,985	76,465
Accounts Payable	4,976	4,052	4,244	1,628	1,176	1,508
Accrued Expenses	-	1,250	-	400	570	167
Current Portion of Long-Term Debt	5,798	5,798	5,941	-	-	-
Current Portion of Leases	870	892	832	176	193	170
Current Income Taxes Payable	879	322	4,640	260	279	29
Current Unearned Revenue	-	3,141	1,388	1,450	785	784
Other Current Liabilities	3,818	177	140	178	4,188	327
Total Current Liabilities	16,341	15,632	17,185	4,092	7,191	2,985
Long-Term Debt	53,610	57,727	63,215	27,981	27,440	14,789
Long-Term Leases	2,862	3,483	3,985	1,577	1,638	1,664
Long-Term Deferred Tax Liabilities	815	1,857	1,490	2,922	2,706	2,457
Other Long-Term Liabilities	4,894	4,281	4,513	4,909	542	2,189
Total Liabilities	78,522	82,980	90,388	41,481	39,517	24,084
Common Stock	47,450	47,172	46,807	41,335	41,036	40,220
Additional Paid-In Capital	21,600	35,074	34,048	29,525	29,100	30,452
Retained Earnings	-11,130	-20,942	-16,104	-8,911	-9,768	-10,785
Treasury Stock	-3	-3	-1	-1	-	-
Comprehensive Income & Other	7,739	7,217	2,060	-4,012	-2,900	-7,506
Total Common Equity	65,656	68,518	66,810	57,936	57,468	52,381
Shareholders' Equity	65,656	68,518	66,810	57,936	57,468	52,381
Total Liabilities & Equity	144,178	151,498	157,198	99,417	96,985	76,465
Total Debt	63,140	67,900	73,973	29,734	29,271	16,623
Net Cash (Debt)	-34,679	-31,697	-24,908	36,823	30,816	23,385
Net Cash Growth	-	-	-	19.49%	31.78%	73.27%
Net Cash Per Share	-384.77	-353.24	-301.85	445.85	375.78	294.18
Filing Date Shares Outstanding	90.49	89.9	89.45	81.92	81.52	80.74
Total Common Shares Outstanding	90.49	89.9	89.45	81.92	81.52	80.6
Working Capital	34,986	42,223	47,927	65,850	55,617	39,033
Book Value Per Share	725.52	762.15	746.93	707.20	704.97	649.92
Tangible Book Value	-10,153	-9,086	-10,104	34,053	33,253	26,445
Tangible Book Value Per Share	-112.19	-101.07	-112.96	415.67	407.92	328.12
Order Backlog	-	1,122	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.